| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
42,578 |
34,344 |
$1.37M |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
6,908 |
5,517 |
$784K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
10,083 |
8,503 |
$438K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
5,975 |
5,880 |
$433K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
5,167 |
5,128 |
$403K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
5,854 |
4,697 |
$343K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
3,444 |
3,415 |
$292K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
25,744 |
10,599 |
$262K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
10,122 |
9,340 |
$204K |
| 96112 |
|
1,795 |
1,745 |
$176K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
6,032 |
5,416 |
$162K |
| 99429 |
|
3,801 |
3,739 |
$124K |
| 99050 |
|
6,081 |
5,576 |
$83K |
| 30210 |
|
693 |
600 |
$73K |
| 87428 |
|
1,189 |
1,111 |
$50K |
| S8301 |
Infection control supplies, not otherwise specified |
3,803 |
1,866 |
$48K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
8,255 |
6,255 |
$46K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,142 |
869 |
$34K |
| 90461 |
|
7,558 |
6,398 |
$29K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,094 |
1,007 |
$28K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,197 |
1,761 |
$26K |
| 69210 |
|
814 |
756 |
$24K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,992 |
1,728 |
$21K |
| 94010 |
|
756 |
714 |
$18K |
| 99381 |
|
403 |
220 |
$14K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,037 |
962 |
$13K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,184 |
1,180 |
$12K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
251 |
199 |
$10K |
| 80061 |
Lipid panel |
876 |
854 |
$10K |
| 99460 |
|
103 |
93 |
$7K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
143 |
123 |
$7K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
478 |
440 |
$5K |
| 17110 |
|
40 |
40 |
$3K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
35 |
35 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
42 |
32 |
$2K |
| 81003 |
|
1,231 |
1,127 |
$2K |
| 58301 |
|
87 |
59 |
$2K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
32 |
32 |
$1K |
| 99383 |
|
13 |
13 |
$1K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
13 |
13 |
$1K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
765 |
648 |
$1K |
| 83655 |
|
1,404 |
1,380 |
$781.69 |
| 85018 |
|
1,457 |
1,434 |
$773.51 |
| 90677 |
|
798 |
782 |
$764.41 |
| 17250 |
|
21 |
12 |
$742.94 |
| 99215 |
Prolong outpt/office vis |
13 |
13 |
$616.23 |
| 95117 |
|
63 |
25 |
$512.82 |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
453 |
224 |
$437.60 |
| 90473 |
|
40 |
40 |
$420.76 |
| 96380 |
|
22 |
22 |
$419.98 |
| 81025 |
|
60 |
59 |
$412.83 |
| 96160 |
|
3,326 |
3,210 |
$403.05 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
1,876 |
1,627 |
$255.87 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
496 |
423 |
$168.03 |
| 90686 |
|
2,400 |
2,377 |
$125.73 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
13 |
12 |
$85.06 |
| 90672 |
|
351 |
348 |
$78.57 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
363 |
344 |
$45.04 |
| 82947 |
|
13 |
13 |
$41.35 |
| 90697 |
|
658 |
643 |
$2.16 |
| 90651 |
|
1,303 |
1,290 |
$0.05 |
| 90381 |
|
39 |
34 |
$0.04 |
| 90621 |
|
521 |
517 |
$0.03 |
| 90380 |
|
14 |
13 |
$0.02 |
| 90648 |
|
3,090 |
3,030 |
$0.01 |
| 90696 |
|
788 |
777 |
$0.00 |
| 90716 |
|
922 |
911 |
$0.00 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
557 |
548 |
$0.00 |
| 90723 |
|
2,206 |
2,156 |
$0.00 |
| 96127 |
|
309 |
296 |
$0.00 |
| 86701 |
|
420 |
413 |
$0.00 |
| 90620 |
|
12 |
12 |
$0.00 |
| 90707 |
|
920 |
896 |
$0.00 |
| 90633 |
|
2,086 |
2,057 |
$0.00 |
| 90700 |
|
939 |
927 |
$0.00 |
| 90681 |
|
1,761 |
1,701 |
$0.00 |
| 99401 |
|
7,900 |
7,765 |
$0.00 |
| 90734 |
|
1,303 |
1,291 |
$0.00 |
| 90670 |
|
3,040 |
2,956 |
$0.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
560 |
550 |
$0.00 |
| 90715 |
|
762 |
753 |
$0.00 |
| 90710 |
|
841 |
831 |
$0.00 |
| 90685 |
|
589 |
580 |
$0.00 |